Parker Institute for Cancer Immunotherapy
North America, California, United States, San Francisco
Description
Parker Institute for Cancer Immunotherapy coordinates cancer research efforts between scientists, clinicians and partners in the industry.
Investor Profile
Parker Institute for Cancer Immunotherapy has made 11 investments, with 2 in the past 12 months and 18% as lead.
Stage Focus
- Series A (45%)
- Series Unknown (18%)
- Post Ipo Equity (9%)
- Convertible Note (9%)
- Series B (9%)
- Series C (9%)
Country Focus
- United States (91%)
- United Kingdom (9%)
'%3e%3cpath fill='%23012169' d='M0 0v30h60V0z'/%3e%3cpath stroke='%23fff' stroke-width='6' d='m0 0 60 30m0-30L0 30'/%3e%3cpath stroke='%23C8102E' stroke-width='4' d='m0 0 60 30m0-30L0 30' clip-path='url(%23b)'/%3e%3cpath stroke='%23fff' stroke-width='10' d='M30 0v30M0 15h60'/%3e%3cpath stroke='%23C8102E' stroke-width='6' d='M30 0v30M0 15h60'/%3e%3c/g%3e%3c/svg%3e)
Industry Focus
- Biotechnology
- Health Care
- Therapeutics
- Medical
- Cloud Computing
- Life Science
- Genetics
- Manufacturing
- Oncology
- Artificial Intelligence (Ai)
FAQ
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.
